JOIN MAILING LIST

PRESENTATION

PIPELINE

INVESTORS

VIDEO

ABOUT US

Oramed Pharmaceuticals (NASDAQ: ORMP) has developed an innovative technology to transform injectable treatments into oral therapies.

Oramed’s flagship product, an oral insulin capsule, has the potential to better the lives of millions of diabetics around the world – allowing, amongst other things, type 2 patients to begin insulin therapy earlier without fear of needles.

Oramed’s oral insulin is currently in advanced clinical trials under the US FDA for both type 1 and type 2 diabetes.

In addition to oral insulin, the company’s proprietary POD™ technology can be used to orally administer a number of protein-based therapies, which are available only via injection.

PRESS RELEASES

Oramed Announces $6.5 Million Milestone Payment from HTIT

June 21st, 2016|

Payment comes in wake of positive topline phase IIB results

JERUSALEM, June […]

Oramed to Present at the American Diabetes Association 76th Scientific Sessions

June 9th, 2016|

JERUSALEM, June 9, 2016 /PRNewswire/ —

Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (http://www.oramed.com), a […]